Diabetes mellitus reduces the therapeutic effectiveness of interferon-?2b plus ribavirin therapy in patients with chronic hepatitis C-Reference-Cited by-同舟云学术

Diabetes mellitus reduces the therapeutic effectiveness of interferon-?2b plus ribavirin therapy in patients with chronic hepatitis C

Published:2007-05 Issue:5 Volume:37 Page:331-336
ISSN:1386-6346
Container-title:Hepatology Research
language:en
Short-container-title:Hepatology Research

Author:

Konishi Ichiro,Horiike Norio,Hiasa Yoichi,Tokumoto Yoshio,Mashiba Toshie,Michitaka Kojiro,Miyake Yasuyuki,Nonaka Suguru,Joukou Kouji,Matsuura Bunzo,Onji Morikazu

Publisher

Wiley

Subject

Infectious Diseases,Hepatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1872-034X.2007.00052.x/fullpdf

Reference37 articles.

1. Hepatitis C virus infection is associated with the development of hepatocellular carcinoma.

2. Interferon Alfa-2b Alone or in Combination with Ribavirin as Initial Treatment for Chronic Hepatitis C

3. Interferon Alfa-2b Alone or in Combination with Ribavirin for the Treatment of Relapse of Chronic Hepatitis C

4. Pretreatment serum hepatitis C virus RNA levels and hepatitis C virus genotype are the main and independent prognostic factors of sustained response to interferon alfa therapy in chronic hepatitis C*1

Cited by 29 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Outcomes and Follow-Up after Hepatitis C Eradication with Direct-Acting Antivirals;Journal of Clinical Medicine;2023-03-12

2. HCV infection characteristics, treatment uptake and outcomes in patient with diabetes mellitus;BMC Endocrine Disorders;2022-11-12

3. Diabetes Mellitus and Risk of Hepatic Fibrosis/Cirrhosis;BioMed Research International;2019-04-04

4. Simple score to predict risk of hepatocellular carcinoma in chronic hepatitis C patients with advanced fibrosis after pegylated interferon and ribavirin therapy;Therapeutics and Clinical Risk Management;2018-04

5. International therapeutic guidelines for patients with HCV-related extrahepatic disorders. A multidisciplinary expert statement;Autoimmunity Reviews;2017-05